Ardelyx (ARDX) Non-Current Assets (2013 - 2026)
Ardelyx (ARDX) reported Non-Current Assets of $122.6 million for Q1 2026, up 25.78% on a YoY basis from $97.5 million in Q1 2025, and up 2.81% quarter-over-quarter from $119.3 million in Q4 2025.
Ardelyx (ARDX) Non-Current Assets (2013 - 2026) Analysis & Trends
Ardelyx has reported Non-Current Assets for 14 years, with the latest figure at $122.6 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 25.78% year-over-year to $122.6 million; the trailing twelve-month figure through Mar 2026 stood at $475.3 million (up 39.37% YoY), and the FY2025 full-year result was $119.3 million, up 50.42% from the prior year.
- Non-Current Assets for Q1 2026 stood at $122.6 million, up from $119.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $122.6 million in Q1 2026, with the low at $15.2 million in Q1 2022.
- Historically, Non-Current Assets has averaged $70.2 million across 5 years, with a median of $79.3 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets retreated 5.34% — and 2023, when it jumped 229.13%.
- Ardelyx's Non-Current Assets stood at $36.5 million in 2022, then jumped by 41.15% to $51.5 million in 2023, then jumped by 54.08% to $79.3 million in 2024, then soared by 50.42% to $119.3 million in 2025, then increased by 2.81% to $122.6 million in 2026.
- The last three Non-Current Assets figures came in at $122.6 million (Q1 2026), $119.3 million (Q4 2025), and $118.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 122.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 122.64 Mn |
| Dec 31, 2025 | 119.29 Mn |
| Sep 30, 2025 | 118.19 Mn |
| Jun 30, 2025 | 115.20 Mn |
| Mar 31, 2025 | 97.50 Mn |
| Dec 31, 2024 | 79.30 Mn |
| Sep 30, 2024 | 83.77 Mn |
| Jun 30, 2024 | 80.47 Mn |
| Mar 31, 2024 | 84.44 Mn |
| Dec 31, 2023 | 51.47 Mn |
| Sep 30, 2023 | 48.16 Mn |
| Jun 30, 2023 | 49.09 Mn |
| Mar 31, 2023 | 49.97 Mn |
| Dec 31, 2022 | 36.46 Mn |
| Sep 30, 2022 | 24.80 Mn |
| Jun 30, 2022 | 17.50 Mn |
| Mar 31, 2022 | 15.18 Mn |
| Dec 31, 2021 | 16.26 Mn |
| Sep 30, 2021 | 17.47 Mn |
| Jun 30, 2021 | 18.49 Mn |